Search
Connect Biopharma Holdings Ltd
CNTBAdd to Watchlist
2.380USD
-0.100-4.03%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
149.85MMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-4.03%
5 Days
+0.85%
1 Month
-20.40%
6 Months
+12.26%
Year to Date
-15.60%
1 Year
+216.91%
TradingKey Stock Score of Connect Biopharma Holdings Ltd
Currency: USD Updated: 2026-05-15Key Insights
Connect Biopharma Holdings Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered undervalued, ranking 122 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.90.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Connect Biopharma Holdings Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Connect Biopharma Holdings Ltd Highlights
StrengthsRisks
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Growing
The company is in a growing phase, with the latest annual income totaling USD 64.00K.
Overvalued
The company’s latest PE is -2.07, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 29.94M shares, increasing 21.31% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 143.10K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.52.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
7.900
Target Price
+218.55%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Connect Biopharma Holdings Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Connect Biopharma Holdings Ltd Info
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Ticker SymbolCNTB
CompanyConnect Biopharma Holdings Ltd
CEOQuart (Barry D)
Websitehttps://www.connectbiopharm.com
Related Instruments
-0.03%
-1.75%
-0.15%
-1.11%
-1.77%
-1.79%
-2.22%
-1.88%
-2.35%
-1.63%
+0.43%
-2.99%
-0.37%
-1.64%
+1.79%
0.00%
-2.05%
-0.15%
-2.77%
+0.41%Popular Instruments
102.160
+3.297 (+3.33%)
300.230
+2.020 (+0.68%)
225.320
-10.420 (-4.42%)
4538.710
-111.520 (-2.40%)
482.020
-7.101 (-1.45%)
1407.610
+24.890 (+1.80%)
724.660
-51.350 (-6.62%)
396.780
-4.290 (-1.07%)
78027.780
-203.220 (-0.26%)
422.240
-21.060 (-4.75%)
